A Review of COVID-19 Vaccine Adverse Event Following Immunization Case Reports by four CARICOM Countries to VigiBase

Authors

  • Danini Marin GEM Consulting

DOI:

https://doi.org/10.21423/JRS.REGSCI.121283

Keywords:

COVID-19 vaccines, Pharmacovigilance

Abstract

The World Health Organization declared COVID-19 a pandemic on 12 March 2020. One of the strategies to combat the pandemic was the development of novel COVID-19 vaccines. Once these vaccines were deployed, immunizations followed. The objective of this study was to identify the characteristics of case reports of adverse events following immunization (AEFIs) with COVID-19 vaccines based on Individual Case Safety Reports (ICSRs) in VigiBase, submitted by four CARICOM countries: Barbados, Haiti, Jamaica and St. Vincent and the Grenadines. A review of the publicly available data on AEFIs with COVID-19 vaccines based on ICSRs in VigiBase was conducted from March 1, 2021 to December 14, 2022. A total of 1,582 AEFI case reports were identified for this period. Most of these were non-serious events, involving persons under 65 years (84.9%), and females (74.1%); 19% were classified as serious events. The top age group reported for AEFIs in VigiBase were 18-44 years (46.6%). The most frequently reported reactions were headache (29.3%), pyrexia (19.3%), dizziness (19.3%). Altogether for the four countries, the AEFIs per 100,000 doses was 64.1 and 12.2 serious AEFIs per 100,000 doses. Recommended actions identified were strengthening national pharmacovigilance regulatory frameworks, establishing robust national pharmacovigilance centres, capacity building of professionals, enhancing communication with key stakeholders and consider relying in a regional pharmacovigilance system.

References

Amarasinghe, A., Cho, H., Katalbas, E. R., & Takashima, Y. (2023). COVID-19 vaccine-related adverse events following immunization in the WHO Western Pacific Region, 2021–2022. Available from: https://ojs.wpro.who.int/ojs/index.php/wpsar/article/view/1046 (Accessed on July 10, 2024)

Caribbean Public Health Agency (CARPHA). (2020). COVID-19 SITUATION REPORT NO. 259 DECEMBER 15, 2022. Available from: https://www.carpha.org/Portals/0/Documents/COVID%20Situation%20Reports/Situation%20Report%20259%20-%20December%2015%202022.pdf (Accessed on July 10, 2024)

Caribbean Public Health Agency (CARPHA). (2022). VigiCarib News December 2022. Available from: https://www.paho.org/en/documents/vigicarib-news-december-2022 (Accessed on July 10, 2024)

DIS TV. (2021). PAHO Farmacovigilancia de Eventos Supuestamente Atribuibles a Vacunación o Inmunización de COVID-19. DIS TV. Available from: https://www.youtube.com/watch?app=desktop&v=gmKZGc7J8LY (Accessed on July 10, 2024)

Jamaica Information Service (JIS). (ND_ Few Reports of Side Effects. Jamaica Information Service. Available from: https://jis.gov.jm/few-reports-of-side-effects/ (Accessed on July 10, 2024)

Ministére de la Santé Publique et de la population. (n.d.). Direction de la Pharmacie. Available from: https://www.mspp.gouv.ht/dpmmt/views/front/pharmacovigilance.php (Accessed on July 10, 2024)

Ministry of Health and Wellness. (2023) VigiAccess. Jamaica: Ministry of Health and Wellness. Available from: https://www.moh.gov.jm/standards-and-regulation-division/pharmacovigilance/ (Accessed on July 10, 2024)

Ogar, C. K., Quick, J., Gilbert, H. N., Vreman, R. A., Mantel-Teeuwisse, A. K., & Mugunga, J. C. (2023). Adverse Events to SARS-CoV-2 (COVID-19) Vaccines and Policy Considerations that Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries: A Mixed Methods Study. Drug Safety, 46(4), 357–370. Available from: https://doi.org/10.1007/s40264-023-01279-3 (Accessed on July 10, 2024)

Oosterhuis, I., Scholl, J., Van Puijenbroek, E., Kant, A., & Van Hunsel, F. (2022). Optimizing safety surveillance for COVID-19 vaccines at the National Pharmacovigilance Centre LAREB: One year of COVID-19 vaccine experience. Drug Safety, 46(1), 65–75. Available from: https://doi.org/10.1007/s40264-022-01253-5 (Accessed on July 10, 2024)

Pan American Health Organization (PAHO). (2022). Terms of Reference: Pharmacovigilance officer surveillance of adverse drug reactions due to covid-19 vaccines. Available from: https://www.paho.org/sites/default/files/terms_of_reference_pharmacovigilance_officer_surveillance_of_adverse_drug_reactions_due_to_covid-19_vaccines_0.pdf (Accessed on July 10, 2024)

Pan American Health Organization (PAHO). (2023). COVID-19 Vaccination in the Americas Dashboard: Week 52, 2021. Available from: https://ais.paho.org/imm/IM_DosisAdmin-Vacunacion.asp (Accessed on July 10, 2024)

Pan American Health Organization (PAHO). (n.d.). Haiti: Country Profile for COVID-19 Vaccination. Available from: https://im-data-paho.github.io/cov19-country-profiles/en/report_HTI.html (Accessed on July 10, 2024)

Pan American Health Organization (PAHO) (2020). Post-authorization Surveillance of Medical Products during a Pandemic Emergency. Available from: https://covid-19pharmacovigilance.paho.org/img/recursos/60783d0f4550988aa8bd763c3.pdf (Accessed on July 10, 2024)

GIS. (2021). Drug Service survey on vaccine side effects. Government Information Service. Available from: https://gisbarbados.gov.bb/blog/drug-service-survey-on-vaccine-side-effects/ (Accessed on July 10, 2024)

Rudolph, A., Mitchell, J., Barrett, J., Sköld, H., Taavola, H., Erlanson, N., Melgarejo-González, C., & Yue, Q. (2022). Global safety monitoring of COVID-19 vaccines: how pharmacovigilance rose to the challenge. Therapeutic Advances in Drug Safety, 13, 204209862211189. Available from: https://doi.org/10.1177/20420986221118972 (Accessed on July 10, 2024)

St. Vincent and the Grenadines. Public Health (Emergency Authorization of COVID-19 Vaccine) Rules (2021). Available from: https://health.gov.vc/health/images/stories/PDF/SRO-Public_Health_Emergency_Authorisation_of_Covid-19_Vaccine.pdf (Accessed on July 10, 2024)

Uppsala Monitoring Centre. (n.d.). The WHO Programme for international Drug Monitoring. Available from: https://who-umc.org/about-the-who-programme-for-international-drug-monitoring/ (Accessed on July 10, 2024)

UWItv. (2021). Pharmacovigilance: monitoring the safety of COVID-19 vaccines in Barbados. Available from: https://fb.watch/mO54-meBHb/ (Accessed on July 10, 2024)

Walker, K. E., Bankay, R., Jankie, S., & Dhingra, S. (2023). Pharmacovigilance in the Caribbean Countries: an Overview. Current Pharmacology Reports, 9(4), 217–227. Available from: https://doi.org/10.1007/s40495-023-00320-4 (Accessed on July 10, 2024)

Watson, O. J., Barnsley, G., Toor, J., Hogan, A. B., Winskill, P., & Ghani, A. C. (2022). Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet. Infectious Diseases/the Lancet. Infectious Diseases, 22(9), 1293–1302. Available from: https://doi.org/10.1016/s1473-3099(22)00320-6 (Accessed on July 10, 2024)

World Health Organization. (2020). COVID-19 Vaccine Safety Surveillance manual. 1st edition. Available from: https://www.who.int/docs/default-source/covid-19-vaccines-safety-surveillance-manual/covid19vaccines_manual_aefi_20210104.pdf (Accessed on July 10, 2024)

World Health Organization. (2020). COVID-19 vaccines: safety surveillance manual. Available from: https://apps.who.int/iris/handle/10665/338400 (Accessed on July 10, 2024)

World Health Organization. (2023). Pharmacovigilance. Available from: https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance (Accessed on July 10, 2024)

Journal of Regulatory Science - Volume 12 Issue 1

Downloads

Published

2024-07-12 — Updated on 2024-07-16

Versions

Issue

Vol. 12 No. 1 (2024)

Section

Review Articles

License

Copyright (c) 2024 Danini Marin

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

By submitting content to the Journal of Regulatory Science (JRS), authors agree to the following terms:

  1. Authors retain copyright and grant the JRS the right of first publication. Authors retain patent, trademark, and other intellectual property rights (including research data) and grant third parties the right to use, reproduce, and share the article according to the Creative Commons — Attribution-NonCommercial 4.0 International — CC BY-NC 4.0 license agreement. The JRS is an open access journal and, as a result, articles are free to use with proper acknowledgment of the work's authorship and initial publication in this journal.

  2. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process.

  3. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article.

  4. The publication of the submission has been approved by all co-authors and responsible authorities at the institute or organization where the work has been carried out.

  5. Copyright has not been breached in seeking publication of the submission.

How to Cite

A Review of COVID-19 Vaccine Adverse Event Following Immunization Case Reports by four CARICOM Countries to VigiBase. (2024). Journal of Regulatory Science, 12(1). https://doi.org/10.21423/JRS.REGSCI.121283 (Original work published 2024)